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New Sequencing technologies 
help revealing unexpected 
mutations in Autosomal Dominant 
Hypercholesterolemia
Sandy Elbitar  1,2,3, Delia Susan-Resiga  4, Youmna Ghaleb1,2,3, Petra El Khoury1,2, Gina 
Peloso5, Nathan Stitziel6, Jean-Pierre Rabès  1,7, Valérie Carreau8, Josée Hamelin4, Ali Ben-
Djoudi-Ouadda4, Eric Bruckert8, Catherine Boileau1,3,9, Nabil G. Seidah4, Mathilde Varret  1,3 
& Marianne Abifadel1,2
Autosomal dominant hypercholesterolemia (ADH) is characterized by elevated LDL-C levels leading 
to coronary heart disease. Four genes are implicated in ADH: LDLR, APOB, PCSK9 and APOE. Our aim 
was to identify new mutations in known genes, or in new genes implicated in ADH. Thirteen French 
families with ADH were recruited and studied by exome sequencing after exclusion, in their probands, 
of mutations in the LDLR, PCSK9 and APOE genes and fragments of exons 26 and 29 of APOB gene. 
We identified in one family a p.Arg50Gln mutation in the APOB gene, which occurs in a region not 
usually associated with ADH. Segregation and in-silico analysis suggested that this mutation is disease 
causing in the family. We identified in another family with the p.Ala3396Thr mutation of APOB, 
one patient with a severe phenotype carrying also a mutation in PCSK9: p.Arg96Cys. This is the first 
compound heterozygote reported with a mutation in APOB and PCSK9. Functional studies proved 
that the p.Arg96Cys mutation leads to increased LDL receptor degradation. This work shows that 
Next-Generation Sequencing (exome, genome or targeted sequencing) are powerful tools to find new 
mutations and identify compound heterozygotes, which will lead to better diagnosis and treatment of 
ADH.
Hypercholesterolemia is a major risk factor for atherosclerosis and its premature cardiovascular complications. 
Autosomal dominant hypercholesterolemia (ADH) (MIM # 143890) is one of the most common monogenic dis-
orders. It is caused by mutations in genes encoding key proteins involved in the LDL receptor (LDLR) endocytic 
and recycling pathways, causing decreased cellular uptake of LDL and increased plasma LDL-cholesterol (LDL-C) 
concentrations. Elevated plasma LDL-C levels give rise to tendon and skin xanthomas, arcus cornea, and vascular 
deposits, leading to progressive and premature atherosclerosis and coronary heart disease (CHD)1. Four genes 
are known to be implicated in the disease: LDLR, the gene encoding the low-density lipoprotein receptor2; APOB, 
which encodes the apolipoprotein B3, the ligand of the LDL receptor; PCSK9 (Proprotein convertase subtilisin 
kexin 9)4, which encodes a serine protease5 that plays a role in the degradation of the LDLR independently of its 
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catalytic activity6; and APOE7. Mutations in LDL Receptor Adaptor protein 1 (LDLRAP1) gene are responsible of 
the recessive form of the disease8.
The prevalence of ADH is approximately estimated to 1/217 in Northern Europe9,10 but varies geographically 
from a region to another and is higher in some populations due to a founder effect11. Recent studies showed that 
ADH is under-diagnosed and undertreated in the general population12 and the probability of identifying a genetic 
component in individuals with hypercholesterolemia increases when LDL-C levels increased10.
The respective contribution of each known gene to ADH slightly varies from one country to another. A study 
in a French cohort, which included probands and families with hypercholesterolemia recruited through the 
French Research Network for ADH from several regions of France, showed that the LDLR gene is implicated in 
73.9% of the cases, while mutations in APOB and PCSK9 are responsible of 6.6% and 0.7% of the cases respec-
tively. Nevertheless, in 18.8% of the ADH probands studied, no mutation was found13.
Genetic diagnosis of ADH was generally performed by direct DNA sequencing or a combination of direct 
sequencing with the multiplex ligation-dependent probe amplification (MLPA) to detect large insertion or dele-
tion mutations in genes known to be implicated in the disease. Concerning the APOB gene, the p.Arg3527Gln, 
also known as APOB3527 or APOB3500, is the first and most common ADH-related mutation in APOB reported 
in late 1980s3. It is responsible alone for more than 95% of Familial Defective apolipoprotein B cases (FDB)14 
(MIM# 144010). A few other mutations leading to hypercholesterolemia were described in the following years 
and were all located in a specific region of the APOB gene. Therefore, this gene was not classically entirely studied 
in ADH by Sanger sequencing and routinely only a fragment of exon 26 and another of exon 29 are analyzed, 
covering the regions where the functional mutations causing hypercholesterolemia have been described15,16.
Targeted next-generation sequencing (NGS) panel is now currently used to screen for ADH-causing muta-
tions10,17, while exome sequencing (targeted sequencing of all protein-coding regions of the genome) is used 
to identify mutations in new genes. This approach, now slowly substituted by whole genome sequencing, has 
emerged as an effective tool for gene discovery in families with suspected monogenic disorders18.
The aim of our study was to investigate the genetic causes of ADH in French probands. After the exclusion 
in 127 ADH probands, of mutations in the LDLR, APOE and PCSK9 genes and fragments of exons 26 and 29 
of APOB, thirteen ADH families were recruited. Two or three affected members of each family were studied by 
exome sequencing in order to identify new mutations in known genes or in new genes, which will eventually lead 
to a better understanding of the mechanism of this disease.
Results
A double heterozygous patient with a mutation in APOB and PCSK9 in HC138 family. Exome 
sequencing was used to investigate the genetic cause of ADH in the HC138 family using DNA from patients I.1 
and II.1 (Fig. 1). The proband II.1 had a history of arcus cornea with high levels of total-cholesterol (201 mg/dL) 
Figure 1. Pedigree of family HC138 with status of the p.Ala3396Thr mutation of APOB and the p.Arg96Cys of 
PCSK9 for each patient. (A) Lipid levels are given when available in mg/dL with the age at clinical measurement. 
The −/− indicates the absence of the mutation while +/− indicates the heterozygous carriers. The asterisk 
shows the patients studied by exome sequencing. (B–C) Conservation of the alanine at position 3396 of 
APOB and the arginine at position 96 of PCSK9 between different species. In-silico prediction analysis of both 
mutations using Polyphen, Sift, and Mutation taster tools.
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and LDL-C (130 mg/dL) despite treatment by rosuvastatin 10 mg and Ezetimibe. His father I.1 suffered from 
myocardial infarction at the age of 50. He also presented arcus cornea and had a very high level of total-choles-
terol reaching 440 mg/dL before he started statin treatment. The familial autosomal dominant transmission was 
confirmed by the recruitment of other members of the family. Details of their clinical measurements are given in 
Fig. 1A.
Exome sequencing of the two patients allowed the identification of the c.10186 G > A mutation in exon 26 of 
the APOB gene, which led to the substitution p.Ala3396Thr as previously described19. This mutation was then 
confirmed by Sanger sequencing. It segregated with the disease in the family with a penetrance of 100% and 
with no phenocopy. It was not reported in the different databases: Exome Variant Server (evs.gs.washington.
edu/EVS/), dbSNP (ncbi.nlm.nih.gov/SNP/), and gnomAD browser (gnomad.broadinstitute.org/). The in-silico 
bioinformatics tools predicted that it is disease causing, and showed a high conservation of the alanine at position 
3396 among different species (Fig. 1B).
Furthermore, exome sequencing analysis showed in patient I.1 a variation in exon 2 of PCSK9: c.286 C > T 
leading to the p.Arg96Cys substitution. This variant was confirmed by Sanger sequencing. It was not carried by 
any other member of the family (Fig. 1A). The p.Arg96Cys (rs185392267) is reported with a very low frequency of 
2.166e-5 (only 6 times over 277054 in gnomAD browser). The arginine at position 96 is highly conserved among 
species and its replacement by a cysteine is predicted to be pathologic by the in silico prediction tools (Fig. 1C).
Characterization of the p.Arg96Cys PCSK9 mutation. Functional analyses were performed to study 
the effect of the p.Arg96Cys PCSK9 mutation on PCSK9 maturation and on PCSK9-mediated LDLR degrada-
tion. PCSK9-WT and p.Ser127Arg (S127R), a well-characterized gain-of-function (GOF) mutation, were used 
as controls. Cell-based functional characterizations of wild-type (WT) PCSK9 and mutants R96C and S127R in 
HEK293 and HepG2 cells are shown in Fig. 2. Biosynthetic analysis (Fig. 2A), Western Blot (WB) (Fig. 2B) and 
Elisa (Fig. 2C) analyses for PCSK9 showed that the p.Arg96Cys mutation results in increased cellular levels of 
total PCSK9 (~60%), reduced processing of proPCSK9 zymogen to PCSK9 (by ~30%), and decreased PCSK9 
secretion (by ~60%) relative to WT protein. Overexpression of PCSK9-R96C results in significantly increased 
LDLR degradation compared to PCSK9-WT. This was confirmed by WB and by Elisa assays for total overex-
pressed LDLR after V5-tagged LDLR was co-transfected in HEK293 cells with V5-tagged PCSK9-WT (WT), 
PCSK9-R96C (R96C), PCSK9-S127R (S127R) or empty vector (V), as control (Fig. 2D), or in HepG2 cells 
(Fig. 2E). Similar results were obtained for endogenous LDLR in HepG2 cells after overexpression of WT and 
mutants PCSK9 (Fig. 2F). Measurement of Dil-LDL uptake under these conditions (Fig. 2F, right panel), showed 
that R96C PCSK9, like the GOF S127R, was significantly more potent than WT PCSK9 in reducing LDL uptake. 
However, when added extracellularly to HepG2 cells for short or long times, PCSK9-R96C degraded endogenous 
LDLR to the same extent as PCSK9-WT (Fig. 2G).
A new mutation p.Arg50Gln in APOB, causing ADH. Furthermore, exome sequencing was performed 
in the HC706 family using DNA from II.6, II.7 and III.2 affected individuals (with asterisk in Fig. 3). The female 
proband (III.2) presented high levels of total cholesterol (235 mg/dL) and LDL-C (155 mg/dL) at the age of 44 
even after treatment with rosuvastatin 20 mg and Ezetimibe. Family history indicated that her 65 years-old father 
(II.1) had a level of total cholesterol of 300 mg/dL before treatment, and kept high levels of total cholesterol 
(246 mg/dL) and LDL-C (149 mg/dL) at 65 years old under treatment. Interestingly, a paternal aunt (II.6) also 
had a history of elevated level of total cholesterol (315 mg/dL before treatment) that reached 253 mg/dL on statin 
treatment with a LDL-C level of 148 mg/dL at the age of 68. Additionally, a paternal uncle (II.7) presented a level 
of total cholesterol of 410 mg/dL and LDL-C level of 319 mg/dL at the age of 37 before starting statin treatment. 
Recruitment of other family members and further investigations confirmed the autosomal dominant trait. Lipid 
measurements of the different members of the family before treatment (when available) or after are provided in 
Fig. 3A.
A substitution c.149 G > A in exon 3 in the APOB gene causing a missense variant p.Arg50Gln was identified 
in the three affected members studied by exome sequencing. Sanger sequencing was used to validate the variation 
and showed that the variation segregated with the disease in the family with a penetrance of 91% and absence of 
phenocopy. Only one case of incomplete penetrance was detected over the eleven studied members of the family 
for whom DNA were available: individual III.8 who carries the variation but does not present high lipid levels as 
depicted in Fig. 3. This variant is not reported in the databases. The arginine residue at position 50 is a conserved 
amino acid in different species (Fig. 3B). The p.Arg50Gln variant is predicted to be damaging by bioinformatics 
tools such as Sift, mutation taster and Polyphen-2 as shown in Fig. 3C.
Subsequently, we analyzed by Sanger sequencing the DNA of 127 French probands with hypercholesterolemia 
in whom we excluded the known mutations in LDLR, APOE and PCSK9 genes and fragments of exons 26 and 29 
of APOB, to look for the p.Arg50Gln variation in the APOB gene. None of those probands carried this variation.
Discussion
In this study, we show that new sequencing technologies like exome sequencing are powerful tools to find new 
mutations in genes already known to be implicated in ADH, APOB in particular, especially because the Sanger 
sequencing strategies classically performed in ADH genetic diagnosis do not target the entire region of APOB. 
Indeed, we identified by exome sequencing in 2 unrelated French ADH families, 2 new mutations in the APOB 
gene, p.Arg50Gln and p.Ala3396Thr which are not located in the regions of exons 26 and 29 routinely investigated 
using Sanger sequencing when searching for APOB mutations implicated in ADH. In fact, direct Sanger sequenc-
ing has been classically targeting only these particular regions due to the size of the apoB (4536 amino acids) and 
because the previously described functional ADH mutations are located in these specific regions of the gene15,16 
(Fig. 4). Although numerous other mutations of APOB were reported in its entire coding-region, these mutations 
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are known to cause familial hypocholesterolemia (hypobetalipoproteinemia or FHBL) and are mostly nonsense, 
frameshift, or splicing variants that lead to various C-terminally truncated apoB species20 (Fig. 4). As for FDB, the 
most common mutation associated with an ADH phenotype is the p.Arg3527Gln carried by approximately 0.1% 
of Northern Europeans and US Caucasians. In addition, the p.Arg3527Trp variant is known to make a significant 
contribution to familial hypercholesterolemia among East Asians21. Few APOB mutations were proven to be 
pathogenic in ADH: p.Arg3507Trp, p.Arg3527Gln, and p.Trp4396Tyr15,22. Despite the fact that these mutations 
are not directly involved in the binding to the LDLR segment that concerns residues 3386 to 339623 (Fig. 4), they 
might destabilize the apoB–LDL receptor interaction by altering some critical residues that are crucial for apoB–
LDL receptor affinity24, which result in a defective receptor-binding23,25. Interestingly, the p.Ala3396Thr mutation 
that we identified recently19 occurs in exon 26 of APOB and is located in the LDLR binding site B of apoB (Fig. 4). 
Consequently, this mutation might lead to a defective apoB-LDLR binding and an abnormal LDL internalization. 
Its good segregation with the disease in the family along with its localization in an important region for the nor-
mal apoB function are strong evidences for its pathogenic effect.
Add to that, the p.Arg50Gln mutation is new and occurs in exon 3 of APOB, a region not routinely analyzed 
in ADH. Several arguments are in favor of a mutation responsible of the ADH phenotype in this family: (1) it 
showed good segregation with the disease in the family, (2) in-silico prediction tools are in favor of its deleterious 
Figure 2. Cell-based functional characterization of PCSK9 wild-type (WT) and p.Arg96Cys (R96C). HEK293 
cells were transiently transfected with V5-tagged PCSK9-WT (WT), PCSK9-R96C (R96C) or empty vector 
(V) (A), or gain of function PCSK9-S127R (S127R) (positive control) (B and C) and analyzed for PCSK9 
cellular expression, zymogen processing and secretion of mature protein. (A) Biosynthetic analysis; 48 h post-
transfection cells were pulsed-labeled with [35S]Met/Cys for 3 h, followed by anti-V5 immunoprecipitation, 
SDS-PAGE and autoradiography. (B) WB analysis using anti V5-HRP. Levels of total cellular and secreted 
PCSK9 were quantified by ELISA and the concentrations are listed. The bands corresponding to proPCSK9 and 
PCSK9 in (B) were quantified, their values normalized to β−Actin and ratios of the value of each form to the 
sum of the two forms were graphed in (C). V5-tagged LDLR was co-transfected with V5-tagged PCSK9-WT, 
PCSK9-R96C, PCSK9-S127R or empty vector, as control, in HEK293 cells (D) or HepG2 cells (E). Transfected 
HEK293 cells were analyzed by WB using anti V5-HRP (D). Total cellular levels of LDLR were quantified from 
the WB and by ELISA for HEK293 cells (D) or by ELISA only for HepG2 cells (E) and were normalized to 
values of the control. (F) HepG2 cells were transiently transfected with V5-tagged PCSK9-WT, PCSK9-R96C, 
PCSK9-S127R or empty vector, as control, and the total cellular endogenous levels of LDLR were quantified by 
ELISA (left). Dil-LDL uptake (right) was measured over 2 h. Measured values are reported as % control. (G) 
HepG2 cells were incubated for 7 h or 18 h with conditioned media from HEK293 cells (produced, illustrated 
and quantified in B): no PCSK9 control-media (V) or PCSK9-media (330 ng/ml), WT, R96C or S127R, and 
analyzed by ELISA for total cellular LDLR. Data are representative of two independent experiments performed 
at least in duplicate, with the exception of (F), where LDLR-ELISA was completed for one experiment 
performed in triplicate, while Dil-LDL uptake was measured in one experiment performed in 16 independent 
replicates per condition. Quantifications are averages ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 (t-test). Full-
length blots of Fig. 2A,B and D are presented in Supplementary Figure 2, where only the lanes selected in Fig. 2 
are labeled.
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Figure 3. Segregation analysis of the p.Arg50Gln mutation of APOB in family HC706: (A) Lipid levels are 
given when available in mg/dL with the age of the patients at clinical measurement. The −/− indicates absence 
of the mutation while +/− indicates heterozygous carriers. The asterisk shows the patients studied by exome 
sequencing. (B) The arginine at position 50 of APOB is a conserved amino acid between different species. 
(C) This mutation is predicted to be probably damaging by Polyphen, tolerated by Sift, and disease causing by 
mutation taster when studied in-silico.
Figure 4. Different mutations reported in APOB, causing hypercholesterolemia (FDB) and 
hypocholesterolemia (FHBL). The APOB gene is constituted of 29 exons. The binding site for the LDL receptor 
originally described as site B is formed primarily by residues 3386–3396 (anciently known by 3359–3369). 
Regions 3475–3635 and 4363–4460 are the ones we classically sequence when looking for APOB mutations in 
ADH. Mutations causing familial hypocholesterolemia (FHBL) are distributed on the entire coding-region, and 
they are mostly nonsense, frameshift, or splicing variants. Few mutations causing hypercholesterolemia (FDB) 
are described in a particular region of APOB, the p.Arg3527Gln mutation being the most frequent one. Some 
others have been recently reported to cause ADH outside the classical regions of APOB, shown in italic; the 
p.Arg50Gln and p.Ala3396Thr are detailed in this article and highlighted in bold.
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effect at the protein level, (3) this variant was never reported before, and thus its rare incidence is in favor of a 
mutation rather than a polymorphism and (4) exome sequencing revealed no other interesting genetic event 
that could be responsible for the ADH phenotype in this family. Furthermore, another ADH causing mutation 
at the same position, the p.Arg50Trp, has been reported in another ADH family26 and was confirmed by exome 
sequencing in the UK10K project27. Thomas et al. showed that the p.Arg50Trp variant of APOB accumulates in 
the circulation of affected carriers, which suggest its defective hepatic uptake. In fact, exon 3 forms a small part of 
the first domain (βα1), which is predicted to direct hepatic assembly of lipoprotein molecules, as well as to affect 
the interaction of LDL particles with lipases and macrophage scavenger receptors. Nevertheless, detailed infor-
mation on the specific role of exon 3 in these processes is not available26.
Furthermore, a recent study identified 2 novel APOB mutations, p.Arg3059Cys and p.Lys3394Asn, both asso-
ciated with a significant decrease in binding to the LDL receptor, despite having a low penetrance when study-
ing the co-segregation in the families16. Another study proved that p.Arg1164Thr and p.Gln4494del of APOB 
presented a 40% decrease in internalization in lymphocytes and HepG2 cells, very similar to APOB352715 even 
though they didn’t show complete penetrance. These results suggest that APOB can carry more ADH causing 
mutations outside of the classically studied regions, which means that all regions of the APOB should be investi-
gated when diagnosing ADH. The arginine at position 50 seems to be crucial for a normal cholesterol metabolism 
since 2 different mutations causing ADH have been identified at this same position. Interestingly, a recent study 
suggested that PCSK9 could bind to amino acid sequences within the N-terminal region of apoB28. Whether or 
not APOB mutations in this region might affect its interaction with other proteins such as PCSK9 for instance are 
still to be uncovered.
Besides the p.Ala3396Thr identified in the HC138 family, the analyses of the variants observed in one of the 
members of this family in whom exome sequencing has been performed, allowed the identification of a new 
mutation in exon 2 of PCSK9: p.Arg96Cys. This patient carrying the 2 mutations in APOB and PCSK9 showed a 
severe phenotype with a maximal level of 440 mg/dL of total cholesterol before statin treatment. He also suffered 
from a myocardial infarction at the age of 50. The p.Arg96Cys mutation of PCSK9 has been recently reported to 
be responsible alone for the ADH phenotype in 3 patients from Denmark14, with mean untreated values of total 
cholesterol of 271.5 ± 46.0 mg/dL and LDL-C of 191.4 ± 34.4 mg/dL. Interestingly, 2 of those 3 patients presented 
coronary artery disease (CAD)14. Our functional studies performed herein demonstrated that the p.Arg96Cys 
mutation is a new GOF mutation of PCSK9, which alone may be responsible for the ADH phenotype. Although 
synthesized in cells at a higher level than the WT protein, the p.Arg96Cys is less secreted compared to WT. When 
overexpressed in cells, this GOF mutant degrades the LDLR to a higher extent than PCSK9-WT. The latter activity 
of PCSK9-R96C correlated with a decreased Dil-LDL uptake in HepG2 cells, an effect similar to that observed 
with the PCSK9-S127R GOF mutant. Interestingly, when added extracellularly to HepG2 cells, PCSK9-R96C 
degraded endogenous LDLR to the same extent as PCSK9-WT, whereas the GOF PCSK9-S127R displayed a sig-
nificantly higher activity toward the LDLR. Collectively, our cell-based data suggest that PCSK9-R96C is a GOF 
mutant that better interacts with LDLR intracellularly (intracellular pathway)29, but similarly at the cell surface 
(extracellular pathway). In the liver, the extracellular pathway is predominant, as wild type PCSK9 acts mostly 
extracellularly on hepatocytes. However, the presence of a mutation on one allele of the PCSK9 gene could result 
in a shift of the prevalence of one pathway over the other, as was also reported for the LDLR-R410S mutation30. 
Thus, genetic evidence together with the cell-based functional characterization of PCSK9-R96C compared to WT 
and S127R are strong enough to conclude that the p.Arg96Cys is a GOF mutation of PCSK9, which alone could 
cause ADH, and aggravate the phenotype when carried together with another ADH causing mutation.
Consequently, exome sequencing helped us identify, in a patient with severe ADH, a mutation in APOB 
together with a new mutation in PCSK9. To the best of our knowledge, this is the first report of an ADH patient 
carrying a mutation in both APOB and PCSK9 genes concomitantly. Unfortunately, parents or other family mem-
bers were not available for further investigations to rule out the possibility of a de-novo mutation that might 
have occurred in the PCSK9 gene in this patient, and that it was not transmitted to his children. These findings 
demonstrate that exome sequencing can help in the diagnosis and the identification of compound heterozygotes 
in ADH. In fact, some studies described patients and families with both LDLR/APOB31–36, or LDLR/PCSK9 muta-
tions37,38. However, the clinical characteristics of double-heterozygous ADH patients are underreported and the 
diagnosis of double-heterozygous ADH can be easily missed39. Thus other APOB/PCSK9 double heterozygous 
might exist. It is noteworthy that the molecular identification of double heterozygosity is very important for fam-
ily screening and adequate ADH diagnosis and treatment of all affected carriers of the family. Furthermore, the 
other genetic event occurring in another gene might explain differences in phenotypes and would be important 
for revealing the cause of phenocopies when studying familial segregation. This underscores the necessity of fully 
screening the LDLR, APOB, PCSK9 and APOE genes in all patients.
In summary, our work shows the importance of next generation sequencing technologies such as exome 
sequencing in identifying new mutations in the genes known to be implicated in ADH, and in revealing double 
heterozygous mutations, which improves familial screening and genetic counseling, as well as understanding 
the transmission of the disease and its severity in different members of the same family. The investigation for 
ADH mutations should include the entire coding regions of LDLR, PCSK9, APOE and APOB, with a particular 
attention to the region of the arginine at position 50 of the APOB. This will improve diagnosis and treatment of 
the disease and prevent its cardiovascular complications. Physicians, clinical biochemists and health profession-
als worldwide should join their effort to fight against this disease by offering the most adequate screening and 
diagnosis of individuals and families with ADH. Thus, genetic studies are of great importance in these extremely 
high-risk individuals and families. They can help implementing the most effective strategies to prevent and treat 
ADH, and might lead to new therapeutic class of lipid lowering drugs like it was the case with the discovery of 
PCSK940.
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Methods
Patients and Families. Probands and families from different cities in France were recruited by The French 
National Research Network on Hypercholesterolemia based on the inclusion criteria previously described13: 
LDL-C levels above the 95th percentile when compared with a sex and age-matched French population 
(STANISLAS cohort, B. Herbeth, G. Siest & S Visvikis-Siest41, personal communication), with normal levels 
of triglycerides and HDL-C, with an autosomal dominant transmission of hypercholesterolemia in the family. 
The study was performed in accordance with French bioethics regulations and all subjects gave informed con-
sent. This study was conducted as part of trial # 05-07-06 approved by French Consultative Committee for the 
Protection of Person in Biomedical Research (CCPPRBs) Paris, Necker.
Sanger Sequencing and MLPA. In all subjects, genes were studied sequentially: first, the p.Arg3527Gln 
mutation of the APOB (NM_000384.2) was looked for as previously described42 and then regions 3475–3635 
and 4363–4460 of APOB were analyzed by Sanger sequencing. The promoters and the 18 exons of LDLR 
(NM_000527.4), as well as close flanking intronic sequences were amplified and sequenced. If no mutation was 
found, the search for a deletion/duplication of one or several LDLR’ exon(s) was performed with SALSA MLPA 
kit (P062) and data were analyzed with Coffalyser software (MRC-Holland). Finally, if no deletion/duplication 
was discovered, the 12 exons of PCSK9 (NM_174936.3) and the 4 exons of APOE (NM_000041.3) as well as 
the flanking intronic regions were sequenced. Primer sequences and annealing temperatures are available upon 
request. Electrophoregrams were analyzed using Gensearch®, or CodonCode Alligner®.
Exome Sequencing. The family members analyzed by exome sequencing where chosen based on DNA 
availability for at least 2 affected members of the family and presence of informed consent allowing for genetic 
studies with prioritization of phenotypic extremes when possible. These selected samples underwent exome 
sequencing at the Broad Institute after that the institutional review board and all participating sites approved the 
study protocols and all individuals who were selected for sequencing provided informed consent as previously 
described19.
Analysis of Exome Sequencing Data. In order to find the causal mutation out of thousands of differ-
ent variations obtained by the exome sequencing, we used a comprehensive framework for prioritizing vari-
ants, which is commonly used in the analysis of exome sequencing studies43. Starting with the total number 
of variants shared by individuals from the family, we excluded variants conflicting with the ADH inheritance 
pattern and common variants that have a frequency of ≥ 1% in the general population, by examining different 
databases such as dbSNP, 1000Genome, Exac and gnomAD browsers. Then, we excluded silent and non-genic 
variants which do not alter protein sequence since most Mendelian syndromes are caused by coding or splice site 
mutations that alter the protein sequence. The remaining single nucleotide variants and short insertions or dele-
tions were considered candidates. The variants were subsequently analyzed separately by exploring those whose 
genes have physical protein-protein interaction with the 4 known genes of ADH, or share the same biological 
pathways. When an interesting variation is found, familial segregation was studied to demonstrate its possible 
co-segregation with the phenotype in the family.
In silico Analyses. The frequency of the variations found by sequencing was estimated using different data-
bases: Exome Variant Server (evs.gs.washington.edu/EVS/), dbSNP (ncbi.nlm.nih.gov/SNP/), and gnomAD 
browser (gnomad.broadinstitute.org/).
The causal effect of each new molecular event was estimated with in silico prediction of protein function tools: 
Polyphen (genetics.bwh.harvard.edu/pph), SIFT (sift.jcvi.org), MutationTaster (mutationtaster.org) using Alamut 
Visual version 2.7.1.
cDNAs, cell culture and transfections. The cDNAs encoding human LDLR30 and human PCSK9 and its 
mutants44 were cloned in pIRES2-EGFP (Clontech Labs), a bicistronic plasmid allowing the independent expres-
sion of a fluorescent EGFP from an internal ribosome entry site (IRES) and C-terminally V5-tagged wild-type 
(WT) human PCSK9 or its p.Arg96Cys (R96C) mutant (identity confirmed by DNA sequencing) under the con-
trol of a CMV promoter. The WT PCSK9 and the GOF PCSK9-S127R44 served as control. HEK293 (human 
embryonic kidney-derived epithelial) and HepG2 (human hepatocellular carcinoma) cells (American Type 
Culture Collection, Manassas, VA) were cultured in Dulbecco’s modified Eagle medium (DMEM) (HEK293 cells) 
or in Eagle minimal essential medium (EMEM) (HepG2 cells) supplemented with 10% (v/v) fetal bovine serum 
(FBS) (Invitrogen) and were maintained at 37 °C under 5% CO2. HEK293 cells were seeded in poly-L-lysine 
(50 µg/mL) coated 12-well plates (3.5 × 105 cells/well) or 10 cm plates (4 × 106 cells/well) for PCSK9 media pro-
duction and the following day transfected using jetPRIME (PolyPlus) and a total of 0.5 µg of cDNA or 6 µg of 
cDNA, respectively. 24 h post-transfection, the culturing medium was changed to serum-free and the cells were 
treated according to each experiment. Alternatively, for media swap experiments, HepG2 cells (3.5 × 105 cells/
well) were seeded in 12-well cell culture plates. 24 h later cells were starved for 24 h in serum-free media and 
following were incubated for 7 h or 18 h with 24 h serum-free conditioned media of HEK293 cells overexpress-
ing human PCSK9 (WT, S127R or R96C) (see above). The concentrations of the secreted PCSK9 into the media 
were measured using an in-house ELISA assay as previously described45. For Dil-LDL uptake experiments and 
LDLR ELISA measurements, HepG2 cells were plated in 96-well plates (0.2 × 105 cells/well) (CellBind black plate 
with clear bottom, Corning; Cat # 3340) or 12-well plates (2 × 105 cells/well), respectively. Transfections were 
performed at the time of seeding with 0.125 µg of cDNA (96-well plate) or 1 µg of cDNA (12-well plate) and 
using FuGENE® HD (Promega). 24 h post-seeding and -transfection, the cells were starved for 24 h in serum-free 
media and treated according to each experiment.
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Biosynthetic Analyses. 48 h post-transfection, HEK293 cells were washed and pulse-labeled for 3 h with 
250 µCi/ml [35S]Met/Cys (PerkinElmer Life Sciences)44. Following 2 washes with ice-cold PBS, the cells were 
lysed in modified radioimmune precipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5; 1% Nonidet 
P-40; 0.5% sodium deoxycholate; 0.1% SDS) and protease inhibitor mixture (Roche Applied Science). Cell lysates 
and media were immunoprecipitated with monoclonal V5-Ab (1:500; Invitrogen) and immunoprecipitates were 
resolved by SDS-PAGE (8% Tris-Tricine gels) followed by autoradiography (2 h at −80 °C).
Human LDLR ELISA in cell lysates. Following the treatments specific to each experiment, HEK293 or 
HepG2 cells were washed twice with ice-cold PBS and lysed on ice with ice-cold, non-denaturing cell lysis buffer 
(20 mM Tris-HCl, pH 8, 137 mM NaCl, 2 mM Na2EDTA, 1% NP-40, 10% glycerol, 4% protease inhibitor cocktail 
without EDTA) for 40 min, with gentle rotation. Cell lysates were cleared by centrifuging for 12 min at 15,000xg at 
4 °C. The supernatants corresponding to the non-denatured cell lysates were saved and subjected to measurement 
of total human LDLR protein levels (human LDLR DuoSet ELISA Development kit, DY218; R&D Systems) and 
of total protein (Bio-Rad DC Protein assay), following the manufacturers’ protocol. The optical densities of the 
colored products were determined using a SpectraMax i3 plate reader (Molecular Devices). All measured LDLR 
concentrations (pg/mL) were corrected for total protein concentration (mg/mL). Corrected LDLR content (pg 
LDLR/ml total protein) is reported as % vector (pIRES-EGFP) control.
Western Blotting. Following the incubation times and treatments specific to each experiment, cultured cells 
were washed and lysed and the lysates cleared, as described above. Thirty to fifty micrograms of protein were sep-
arated on 8% Tris glycine SDS-PAGE gels and transferred to a PVDF membrane. Western blotting was performed 
for human LDLR-V5 and human PCSK9-V5 (anti-V5-HRP, 1:5000; R96125; Invitrogen) and for β-actin (rabbit 
anti-β-actin, 1:5000; A2066; Sigma). After incubation with the appropriate secondary antibodies, if required, the 
membranes were revealed using Clarity Western ECL Substrate (Bio-Rad), imaged with a GelDoc XR+ instru-
ment (Bio-Rad) and the bands of interest quantified using ImageLab 5.2.1 software (Bio-Rad).
Dil-LDL uptake. 48 h post-seeding and -transfection and after a 24 h starvation in serum-free medium, 
HepG2 cells were incubated for 2 h at 37 °C with 6 μg/ml Dil-LDL (Alfa Aesar; Cat # J675330) (20 μl of 36 μg/ml 
Dil-LDL were added to each well containing 100 μl of conditioned media). Each condition was prepared in 16 
replicates. At the end of the 2 h incubation, the media was removed and the cells washed 3 times (200 μl/well) with 
ice-cold D-PBS no ions (Wisent). After the final wash was removed, 100 μl of PBS was added to each well and the 
plate was scanned (bottom read) on a SpectraMax i3 plate reader (Molecular Devices). For each well, raw Dil-LDL 
uptake was measured as the average fluorescence intensity (RFU) (ex: 534 nm/em: 572 nm) of 21 points equally 
distributed in a fill pattern. Dil-LDL uptake in each well was corrected for the total number of transfected cells 
(average EGFP fluorescence intensity; ex: 488 nm/ em: 513 nm) and reported as the fluorescence ratio of Dil-LDL/
EGFP. Corrected Dil-LDL uptake is reported as % vector (pIRES-EGFP) control and was obtained from 16 wells.
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